King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
17:16
Romania supports Spain's efforts to recognize Catalan, Basque, and Galician as official EU languages.
17:14
Cristi Borcea's son, Patrick, would be under electronic monitoring after beating his ex-girlfriend.
17:10
The EU provides 28 billion euros for the defense of Ukraine in 2026, of which 8.5 billion have already been paid.
17:09
Sarajevo Film Festival 2026: Significant Romanian presence at the 32nd edition, supported by the Romanian Cultural Institute
17:04
James Stavridis, former American commander of NATO forces: "Putin cannot break down the NATO door, as he tries to enter through the window."
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
